BioSpace News Archive

Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced the upsizing and pricing of an offering of $600.0 million aggregate principal amount of 3.625% senior notes due 2029 (the “Notes”)

Immunologists have determined the process driving life-threatening inflammation, lung damage and organ failure in patients with COVID-19, sepsis and other inflammatory disorders suggesting possible treatment using existing drugs.

Eli Lilly and Company’s antibody therapeutic will be distributed as part of the federal government’s Operation Warp Speed.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced positive interim clinical results from the ongoing Phase 1b/2a study of VBI-2601 (BRII-179), a novel recombinant, protein-based immunotherapeutic candidate for the treatment of chronic hepatitis B virus (HBV) infection

Global contract manufacturer Lincotek Medical has recently brought casting and finishing under one roof at its plant in Portland, Oregon.

RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica”), announced the addition of Dr. Raymond Douglas, M.D. to its leadership team as Global Head, Scientific Affairs. “We are thrilled to have Dr. Douglas join our organization and are committed to building upon the recent launch success of Upneeq. Dr. Douglas will immediately become an integral member of the organization,” said Brian Markison, Ch

Megadalton Solutions, Inc., an early-stage biotech with expertise in large molecule analysis by Charge Detection Mass Spectrometry, announced the expansion of a collaboration with Waters Corporation to bring CDMS technology to a broader set of applications and potential customers in biopharma.

Aphios International announces the launch of a crowdfunding campaign, Virus-Free Blood: Our Best Defense for Fighting Disease (https://tinyurl.com/y4fojsb3

The Voluntary Escrow serves further validates investors belief and support of Havn Life’s business plan and future growth strategy

AUM Biosciences (AUM), a global, clinical stage healthcare company focused on discovering, acquiring and developing novel oncology therapeutics and Newsoara Biopharma announced today that the companies have entered into a 5-year strategic partnership to co-develop up to 6 oncology drugs in AUM’s pipeline.